Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  fludarabine phosphate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 449 for your search:
Start Over
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140
A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25136, NCT01271010
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25137, NCT01283386
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 4 to 70
Sponsor: Other
Protocol IDs: CDR0000066968, RP 98-15, RPCI-RP-9815, NCI-V99-1527, NCT00003816
Stem Cell Transplant for Bone Marrow Failure Syndromes
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 35 and under
Sponsor: Other
Protocol IDs: MT2000-18, 9504M09637, NCT00176878
Nonmyeloablative Stem Cell Transplant in Elderly
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: Over 60
Sponsor: Other
Protocol IDs: 012000, NCT00382759
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 22
Sponsor: NCI
Protocol IDs: NCI-2012-01834, 2961, U10CA098543, CDR0000064883, COG-2961, CCG-2961, NCT00002798
Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000068650, EORTC-06992-CLL-3, NCT00017108
Phase III Comparison of CLB vs FAMP in Previously Untreated Patients with Intermediate- and High-Risk (Rai Stages I-IV) B-Cell CLL
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CLB-9011, CAN-NCIC-CL1, E-C9011, SWOG-9108, CALGB-9011, CL1
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1813.00, NCI-2009-01532, P30CA015704, P01CA078902, FHCRC-1813.00, 5666, NCT00075478
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM314, 2004-000149-39, NCT00086580
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102-14, BO17072, NCT00090051
Primary Rituximab and Maintenance
Phase: Phase III
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: PRIMA, NCT00140582
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 17 and under
Sponsor: Other
Protocol IDs: TRIAL, TRIAL Relapsed AML 2001/01, NCT00186966
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000454560, GCLLSG-CLL-8, EU-20560, ML17102, GCLLSG-CLL-8/ML17/02, NCT00281918
Start Over